Denggang Fu1,
Biyu Zhang2,
Jinghui Sun1,
Jueping Feng3,
Xin Wang4
1College of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA;
2Key Laboratory of Green Chemical Engineering Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430079, China;
3Wuhan Fourth Hospital, Wuhan, Hubei 430033, China;
4School of Medicine, Jiujiang University, Jiujiang, Jiangxi 332005, China.
For correspondence:- Xin Wang
Email: wangxin0072@126.com Tel:+86 138 7920 8703
Received: 26 January 2024
Revised: 13 September 2024
Accepted: 13 September 2024
Published: 29 October 2024
Citation:
Fu D, Zhang B, Sun J, Feng J, Wang X.
Integrative analysis of inhibitor of DNA-binding expression and prognosis in non-small cell lung cancer. Trop J Pharm Res 2024; 23(10):1605-1616
doi:
10.4314/tjpr.v23i10.3
© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Abstract
Purpose: To investigate the expression and prognosis of inhibitor of DNA-binding (ID) protein family in non-small cell lung cancer (NSCLC). Methods: The mRNA expression and prognostic relevance of ID family using Oncomine, UALCAN, Kaplan-Meier plot, and The Cancer Genome Atlas (TCGA) databases were compiled and analyzed. Also, associations between individual IDs' mRNA expression and clinicopathological features in NSCLC patients were identified using unpaired t-test. Results: There was significantly higher expression of each ID in normal cells compared to NSCLC tissues, including adenocarcinoma (AC) and squamous cell carcinoma (SCC; p < 0.05). High ID1 mRNA expression correlated significantly with worse overall survival in NSCLC, AC, and SCC cases (p < 0.05). Also, increased ID4 mRNA expression predicted significantly better overall survival in NSCLC and AC cases, but not in SCC (p < 0.05). Conclusion: Inhibitor of DNA-binding 1 mRNA predicts poorer survival, whereas ID4 mRNA suggests better survival, particularly in AC. ID2 and ID3 mRNA levels lack significant associations with overall survival, suggesting targeting IDs might represent potential therapeutics for NSCLC. There is the need for validation of these outcomes and mechanistic investigations.
Keywords: Inhibitor of DNA-binding, Non-small cell lung cancer, Gene ex
pression, Prognosis